Beilstein J. Org. Chem.2013,9, 717–732, doi:10.3762/bjoc.9.82
preclinical characterization of lead compounds that may ultimately provide novel drugs to treat patients suffering from ALS.
Keywords: amyotrophic lateral sclerosis (ALS); copper/zinc (Cu-Zn) superoxidedismutase1 (SOD1); glutamate toxicity; neurodegeneration; oxidative stress; Introduction
Amyotrophic
(sALS) and 10% of all cases characterized as familial (fALS) [4]. Several gene mutations have been identified that contribute to this disorder with 20% of fALS cases being linked to mutations in the copper/zinc (Cu-Zn) superoxidedismutase1 (SOD1) gene [4]. Many cellular pathologies have been
PDF
Graphical Abstract
Figure 1:
FDA-approved riluzole (1) and other ALS drugs currently in phase III clinical trials (2–6).